Verastem, Inc. (VSTM): who owns it and who trades it
As of Nov 16, 2026, VSTM insiders reported 32 open-market sales worth $1.1M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Dan Paterson (CEO), with $835K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Verastem
From the latest filingsOverall: about as much buying as selling. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VSTM
158 funds and institutions reported VSTM shares worth $379M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.5%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 9.19M | 10.47% | $35.1M | +48% |
| Nantahala Capital Management, LLC | 7.17M | 8.16% | $27.4M | +100% |
| Armistice Capital, LLC | 7.02M | 8.00% | $26.8M | +53% |
| Rtw Investments, LP | 6.64M | 7.55% | $25.3M | +1% |
| Deep Track Capital, LP | 5.74M | 6.54% | $21.9M | No change |
| State Street Corp | 5.13M | 5.84% | $19.6M | +46% |
| Rosalind Advisors, Inc. | 3.99M | 4.54% | $15.2M | +86% |
| Vanguard Capital Management LLC | 3.85M | 4.38% | $14.7M | +16% |
| Stonepine Capital Management, LLC | 3.35M | 3.81% | $12.8M | +1% |
| Vanguard Portfolio Management LLC | 3.27M | 3.72% | $12.5M | +332% |
| Foresite Capital Management VI LLC | 3.15M | 3.58% | $12M | No change |
| Goldman Sachs Group Inc | 2.72M | 3.10% | $10.4M | +83% |
| Baker Bros. Advisors LP | 2.50M | 2.85% | $9.5M | +327% |
| Alyeska Investment Group, L.P. | 2.29M | 2.61% | $8.7M | +12% |
| Millennium Management LLC | 2.08M | 2.37% | $7.9M | -14% |
| Geode Capital Management, LLC | 2.07M | 2.36% | $7.9M | +21% |
| AIGH Capital Management LLC | 1.93M | 2.19% | $7.4M | -4% |
| Opaleye Management Inc. | 1.80M | 2.05% | $6.9M | – |
| Balyasny Asset Management L.P. | 1.69M | 1.92% | $6.4M | +312% |
| Qube Research & Technologies Ltd | 1.63M | 1.85% | $6.2M | +10% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VSTM insiders reported $0 of open-market purchases and $1.1M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Dan Paterson | CEO | Sale plan | 1,299 | $9.60 | $12.5K | Form 4 |
| Oct 1, 2026 | Daniel Calkins | CFO | Sale plan | 2,566 | $8.00 | $20.5K | Form 4 |
| Oct 1, 2026 | Dan Paterson | CEO | Sale plan | 44,121 | $8.00 | $353K | Form 4 |
| Sep 21, 2026 | Daniel Calkins | CFO | Sale plan | 55 | $7.70 | $424 | Form 4 |
| Aug 3, 2026 | Dan Paterson | CEO | Sale plan | 1,302 | $5.81 | $7.6K | Form 4 |
| Jun 22, 2026 | Dan Paterson | CEO | Sale plan | 20,871 | $4.18 | $87.2K | Form 4 |
| Jun 22, 2026 | Daniel Calkins | CFO | Sale plan | 4,032 | $4.18 | $16.9K | Form 4 |
| Jun 22, 2026 | Daniel Calkins | CFO | Sale plan | 57 | $4.13 | $235 | Form 4 |
| May 4, 2026 | Dan Paterson | CEO | Sale plan | 806 | $5.82 | $4.7K | Form 4 |
| Feb 4, 2026 | Dan Paterson | CEO | Sale plan | 970 | $6.69 | $6.5K | Form 4 |
| Jan 12, 2026 | Dan Paterson | CEO | Sale plan | 10,321 | $7.16 | $73.9K | Form 4 |
| Jan 12, 2026 | Daniel Calkins | CFO | Sale plan | 5,039 | $7.16 | $36.1K | Form 4 |
| Dec 24, 2025 | Daniel Calkins | CFO | Sale plan | 80 | $7.86 | $629 | Form 4 |
| Dec 16, 2025 | Brian M Stuglik | Director | Sale plan | 592 | $9.14 | $5.4K | Form 4 |
| Dec 16, 2025 | Dan Paterson | CEO | Sale plan | 393 | $9.14 | $3.6K | Form 4 |
| Dec 16, 2025 | Robert E. Gagnon | Director | Sale plan | 283 | $9.14 | $2.6K | Form 4 |
| Dec 11, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.00 | $20K | Form 4 |
| Dec 10, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.07 | $20.1K | Form 4 |
| Dec 9, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.25 | $20.5K | Form 4 |
| Dec 8, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.50 | $21K | Form 4 |
| Dec 5, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.61 | $21.2K | Form 4 |
| Dec 4, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.00 | $20K | Form 4 |
| Dec 3, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.00 | $20K | Form 4 |
| Dec 2, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.32 | $20.6K | Form 4 |
| Dec 1, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.39 | $20.8K | Form 4 |
| Nov 28, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.79 | $21.6K | Form 4 |
| Nov 26, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.32 | $20.6K | Form 4 |
| Nov 25, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.00 | $20K | Form 4 |
| Nov 24, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.00 | $20K | Form 4 |
| Nov 21, 2025 | Paul A. Bunn | Director | Sale plan | 6,250 | $10.00 | $62.5K | Form 4 |
| Nov 21, 2025 | Michael Kauffman | Director | Sale plan | 8,550 | $10.00 | $85.5K | Form 4 |
| Nov 21, 2025 | Dan Paterson | CEO | Sale plan | 2,000 | $10.00 | $20K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Dan Paterson | President and CEO, Director | – | $835K | Nov 3, 2026 |
| Michael Kauffman | Director | – | $85.5K | Nov 21, 2025 |
| Daniel Calkins | Chief Financial Officer | – | $74.7K | Oct 1, 2026 |
| Paul A. Bunn | Director | – | $62.5K | Nov 21, 2025 |
| Brian M Stuglik | Director | – | $5.4K | Dec 16, 2025 |
| Robert E. Gagnon | Director | – | $2.6K | Dec 16, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VSTM short interest
Very high short interest. 21.7% of VSTM shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 10%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 19.67M VSTM shares were sold short, 21.7% of the shares outstanding, up 14.3% from the report before. At the average daily volume of 3.80M shares, buying them all back would take about 5.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 19.67M | 21.72% | +14% | 3.80M | 5.2 |
| Oct 15, 2026 | 17.20M | 18.99% | +15% | 6.91M | 2.5 |
| Sep 30, 2026 | 14.96M | 16.52% | -17% | 2.15M | 7.0 |
| Sep 15, 2026 | 18.03M | 19.91% | -1% | 2.77M | 6.5 |
| Aug 31, 2026 | 18.30M | 20.20% | -3% | 1.67M | 11.0 |
| Aug 14, 2026 | 18.91M | 20.88% | -5% | 1.96M | 9.6 |
| Jul 31, 2026 | 19.83M | 22.57% | -1% | 2.12M | 9.3 |
| Jul 15, 2026 | 20.10M | 22.89% | -17% | 2.94M | 6.8 |
| Jun 30, 2026 | 24.14M | 27.49% | +11% | 3.47M | 7.0 |
| Jun 15, 2026 | 21.77M | 24.79% | +3% | 2.45M | 8.9 |
| May 29, 2026 | 21.21M | 24.15% | +19% | 2.09M | 10.1 |
| May 15, 2026 | 17.87M | 20.35% | +2% | 2.56M | 7.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Verastem company events
Verastem filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementShared information with investors. Filing
- Oct 14, 2026AnnouncementVerastem, Inc. entered into an underwriting agreement with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule I thereto, relating to the underwritten offering, issuance and sale by the Company of: (i) 30,937,500 shares of the Company’s… Filing
- Oct 14, 2026LeadershipDaniel W. Paterson notified the Board of Directors of the Company of his decision to retire as President and Chief Executive Officer of the Company, effective January 1, 2027. Filing
- Aug 7, 2026AgreementVerastem, Inc., entered into Amendment No. 3 to that certain Note Purchase Agreement, dated as of January 13, 2025, as previously amended by Amendment No. 1 dated as of October 31, 2025 and Amendment No. 2 dated as of March 2, 2026 (as so amended, the “Note Purchase Agreement”) by and among the… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 23, 2026AnnouncementThe Company also (i) announced preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375 in patients with advanced KRAS G12D-mutated solid tumors and provided an update on the status of expected key milestones in the development of VS-7375 and (ii) announced its… Filing
- Jun 17, 2026AnnouncementPositive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer On June 17, 2026, the Company announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a trial… Filing
- May 26, 2026VoteReported shareholder vote results. Filing
- May 7, 2026AnnouncementShared information with investors. Filing
- Mar 4, 2026AnnouncementShared information with investors. Filing
- Feb 4, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementShared information with investors. Filing
- Dec 31, 2025AnnouncementRecent Developments Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Following evaluation of interim data from the RAMP 203 clinical trial in advanced KRAS G12C-mutated NSCLC the Company will discontinue the trial to focus resources on clinical… Filing
- Dec 19, 2025LeadershipDeparture of Chief Operating Officer As previously disclosed on December 15, 2025, as of December 19, 2025, Matthew Ros separated from Verastem, Inc. as its Chief Operating Officer. Filing
- Nov 17, 2025AnnouncementVerastem, Inc. entered into an underwriting agreement with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule A thereto, relating to the underwritten public offering, issuance and sale by the Company of: (i) 8,543,794 shares of the… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Verastem financials
Famous investors that hold VSTM
4 of the 50 well-known investors we track reported holding VSTM in their latest 13F filing. The largest position is Steve Cohen's, worth $7.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 901,995 | $7.3M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 295,622 | $2.4M | 0.0% | -86% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 34,940 | $281K | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 18,389 | $148K | 0.0% | -94% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named VSTM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 0.9% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 0.9% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.4% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.8% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.8% |
Questions about Verastem, Inc. (VSTM) stock
Who owns the most VSTM stock?
The largest reported owner of Verastem, Inc. (VSTM) is BlackRock, Inc., with 10.5% of the company. In total, 158 funds and institutions reported holding VSTM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are VSTM insiders buying or selling?
In the last 12 months, VSTM insiders reported no open-market purchases and 32 sales worth $1.1M. The latest trade was on Nov 3, 2026. See every trade.
What is the short interest in VSTM?
As of Oct 30, 2026, 19.67M VSTM shares were sold short, 21.7% of the shares outstanding, up 14.3% from the report before. At the average daily volume of 3.80M shares, buying them all back would take about 5.2 trading days (days to cover). See the history.
Which famous investors hold VSTM?
4 of the 50 well-known investors we track reported VSTM in their latest 13F filing, including Steve Cohen, Israel Englander, Jim Simons. The largest position is worth $7.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.